Amarillo Biosciences (AMAR) Stock Price, News & Analysis

Company Overview

Amarillo Biosciences (OTCMKTS:AMAR) is a biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of complex diseases. The company leverages its proprietary platform technologies and deep expertise in epigenetics, transcriptomics and proteomics to identify and validate drug targets that address unmet medical needs. Headquartered in Midland, Texas, Amarillo Biosciences operates a research laboratory that integrates computational biology, high-throughput screening and medicinal chemistry to advance its pipeline candidates from discovery through preclinical studies.

The core business activities of Amarillo Biosciences include target identification, lead optimization and preclinical testing. The company’s proprietary libraries of small molecules are designed to modulate key biological pathways involved in cancer, inflammatory disorders and metabolic diseases. By focusing on epigenetic regulators and novel mechanisms of action, Amarillo aims to develop first-in-class or best-in-class drug candidates. Collaboration with academic institutions and contract research organizations allows the company to accelerate its discovery efforts and validate the safety and efficacy of its compounds in relevant disease models.

Founded in 2013 as a spin-out from a prominent university research program, Amarillo Biosciences has built a multidisciplinary team of scientists, biochemists and drug development professionals. The leadership team is led by a chief executive officer with more than two decades of experience in pharmaceutical research and a chief scientific officer with a strong background in translational biology. Their combined expertise guides the company’s strategic direction and fosters a culture of innovation aimed at delivering impactful therapies.

Amarillo Biosciences primarily serves the U.S. market but is actively exploring global partnerships to extend its research collaborations and clinical development programs. The company continues to seek opportunities for strategic alliances with biopharmaceutical firms and research foundations to advance its pipeline into human trials. As Amarillo progresses its lead candidates toward clinical milestones, it remains committed to leveraging cutting-edge science to address challenging therapeutic areas and improve patient outcomes.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 6,100 shs
• Average Volume: 18,253 shs
• Market Capitalization: $25.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMAR Stock Analysis - Frequently Asked Questions

How were Amarillo Biosciences' earnings last quarter?

Amarillo Biosciences, Inc. (OTCMKTS:AMAR) released its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.01) earnings per share for the quarter. The firm earned $0.02 million during the quarter.

How do I buy shares of Amarillo Biosciences?

Shares of AMAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amarillo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarillo Biosciences investors own include Fulcrum Therapeutics (FULC), Cerecor (CERC), Neos Therapeutics (NEOS), VIVUS (VVUS), AquaBounty Technologies (AQB), Astria Therapeutics (ATXS) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 11/14/2018
• Today: 7/12/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:AMAR
• CIK: 1014763
• Web: www.amarbio.com
• Phone: 806-376-1741
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.45 million
• Net Margins: -41,453.98%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -574.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.03) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 42,066,000
• Free Float: N/A
• Market Cap: $25.24 million
• Optionable: Not Optionable
• Beta: -0.06